Skip to main content
SpringerLink
Log in

Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation

  • Invasive Electrophysiology and Pacing (EK Heist, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of warfarin, they are associated with increased costs. In this review, we will provide an overview of the cost-effectiveness of NOACs for stroke prevention in AF. Our comments and conclusions are limited to studies directly comparing all available NOACs within the same framework. The available cost-effectiveness analyses suggest that NOACs are cost-effective compared to warfarin, with apixaban likely being most favorable. However, significant limitations in these models are present and should be appreciated when interpreting their results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Go A. Prevalence of atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.

    Article  CAS  PubMed  Google Scholar 

  2. Miyasaka Y, Barnes ME, Bersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.

    Article  PubMed  Google Scholar 

  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.

    Article  CAS  PubMed  Google Scholar 

  4. Pan X, Simon TA, Hamilton M, et al. Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States. J Thromb Thrombolysis. 2014. doi:10.1007/s11239-014-1144-8.

    PubMed Central  PubMed  Google Scholar 

  5. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760–4.

    Article  CAS  PubMed  Google Scholar 

  6. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36:360–6.

    Article  PubMed  Google Scholar 

  7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients with non-valvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  8. Xu Y, Holbrook AM, Simpson CS, et al. Prescribing patterns of novel oral anticoagulation following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open. 2013;1:E115–9.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Baczek VL, Chen WT, Kluger J, et al. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and metaanalysis. BMC Fam Pract. 2012;13:5.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62. This meta-analysis provides an excellent summary of the clinical benefits of NOACs from their clinical trials.

    Article  CAS  PubMed  Google Scholar 

  11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  13. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  14. Guigliano RP, Ruff CT, Braunwald E, et al. Endoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  Google Scholar 

  15. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114–30. Excellent guidelines summarizing the care of patients with AF.

    Article  PubMed  Google Scholar 

  16. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.

    Article  PubMed  Google Scholar 

  17. HCUP Nationwide inpatient sample (NIS). Healthcare cost and utilization project (HCIP). 2007-2009. Agency for Healthcare research and quality, Rockville, MD. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed 25 Apr 2012.

  18. GoodRx.com/ http://www.goodrx.com/. Accessed 2 July 2012.

  19. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit (ODB) Program E-Formulary. Available at: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html. Accessed on 2 Jan 2014.

  20. McKesson Canada Catalogue July 2013.

  21. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–78.

    Article  PubMed  Google Scholar 

  22. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304–22.

    Article  PubMed  Google Scholar 

  23. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224–7.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Harrington AR, Armstrong EP, Nolan PE, Malone D. Cost-effectiveness of apixaban, dabigatran, rivaroxaban and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676–81.

    Article  PubMed  Google Scholar 

  26. Canestaro WJ, Patrick AR, Avron J, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013;6:724–31. This is cost-effectiveness analysis from a US perspective provides an excellent analysis of its limitations. It provides an excellent framework for reading future cost-effectiveness analysis papers.

    Article  PubMed  Google Scholar 

  27. Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16:498–506. This is cost-effectiveness analysis from a Canadian perspective provides an excellent analysis of its limitations. It provides an excellent framework for reading future cost-effectiveness analysis papers.

    Article  PubMed  Google Scholar 

  28. Lip GYH, Konknakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36:192–230.

    Article  PubMed  Google Scholar 

  29. Rognoni C, Marchetti M, Quaglini S, et al. Apixaban, dabigatran, and rivaroxiban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;39:9–17.

    Article  Google Scholar 

  30. Pan X, Kachroo S, Liu X, et al. Real world discontinuation rates with apixaban versus warfarin, dabigatran or rivaroxiban among atrial fibrillation patients newly initiated on anticoagulation therapy. JACC. 2014;63:A415.

    Article  Google Scholar 

  31. Boehringer Ingelheim Canada Ltd. Product monograph–Pradax. January 27, 2012.

  32. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.

    Google Scholar 

  33. Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR‐SMDM Modeling Good Research Practices Task Force Working Group‐6. Med Decis Making. 2012;32:722–32.

    Article  PubMed  Google Scholar 

  34. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.

    Google Scholar 

  35. Micieli A, Bennell MC, Pham B, et al. Identifying future research priorities using value of information analyses: left atrial occlusion devices in atrial fibrillation. J Am Heart Assoc. 2014;3, e001031. This study provides an excellent overview of value of information analyses using stroke prevention in atrial fibrillation to highlight important concepts.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Limone B, Bajker WL, Mearns ES, et al. Common flaws in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. J Clin Epidemiol. 2014;67:1093–102. This study provides an excellent review of the limitations of cost-effectiveness analyses in atrial fibrillation.

    Article  PubMed  Google Scholar 

  37. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12.

    Article  CAS  PubMed  Google Scholar 

  38. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RELY trial. Lancet. 2010;376:975–83.

    Article  CAS  PubMed  Google Scholar 

  39. You JHS. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation—a cost effectiveness analysis. J Gen Intern Med. 2013;29:438–46.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013;127:2414–23. This study was the first to provide a framework to evaluate pharmacologic and non-pharmacologic methods of stroke reduction in patients with atrial fibrillation.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Wijeysundera is supported by a Heart & Stroke Foundation (H&SF) of Canada Distinguished Clinical Scientist Award.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Schulich Heart Centre, Sunnybrook Health Sciences Centre, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Sheldon M. Singh & Harindra C. Wijeysundera

  2. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Harindra C. Wijeysundera

  3. Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada

    Harindra C. Wijeysundera

Authors
  1. Sheldon M. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harindra C. Wijeysundera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheldon M. Singh.

Additional information

This article is part of the Topical Collection on Invasive Electrophysiology and Pacing

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S.M., Wijeysundera, H.C. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. Curr Cardiol Rep 17, 61 (2015). https://doi.org/10.1007/s11886-015-0618-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-015-0618-4

Keywords

Search

Navigation